Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs

P.G.P.M Ziekman; W. den Otter; J.F.V. Tan; E. Teske; J. Kirpensteijn; J.W. Koten; J.J. Jacobs

Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs

P.G.P.M Ziekman, W. den Otter, J.F.V. Tan, E. Teske, J. Kirpensteijn, J.W. Koten, J.J. Jacobs

Faculty of Veterinary Medicine

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Abstract AIM: Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). MATERIALS AND METHODS: Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×10(6) IU IL-2. RESULTS: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs. CONCLUSION: This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.

Original language	English
Pages (from-to)	161-165
Number of pages	5
Journal	Anticancer Research
Volume	33
Issue number	1
Publication status	Published - 2013

Access to Document

Intratumoural Interleukin-2 Therapy Can Induce Regression
Open Access (free)
Final published version, 104 KB

https://ar.iiarjournals.org/content/33/1/161

Cite this

@article{e9c0d40037b24d8ebf6c168af8ffff77,

title = "Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs",

abstract = "Abstract AIM: Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). MATERIALS AND METHODS: Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×10(6) IU IL-2. RESULTS: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs. CONCLUSION: This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.",

author = "P.G.P.M Ziekman and {den Otter}, W. and J.F.V. Tan and E. Teske and J. Kirpensteijn and J.W. Koten and J.J. Jacobs",

year = "2013",

language = "English",

volume = "33",

pages = "161--165",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs

AU - Ziekman, P.G.P.M

AU - den Otter, W.

AU - Tan, J.F.V.

AU - Teske, E.

AU - Kirpensteijn, J.

AU - Koten, J.W.

AU - Jacobs, J.J.

PY - 2013

Y1 - 2013

N2 - Abstract AIM: Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). MATERIALS AND METHODS: Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×10(6) IU IL-2. RESULTS: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs. CONCLUSION: This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.

AB - Abstract AIM: Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). MATERIALS AND METHODS: Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×10(6) IU IL-2. RESULTS: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs. CONCLUSION: This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.

M3 - Article

SN - 0250-7005

VL - 33

SP - 161

EP - 165

JO - Anticancer Research

JF - Anticancer Research

IS - 1

ER -

Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs

Abstract

Access to Document

Fingerprint

Cite this